Alnylam Pharmaceuticals Press Release | Sep 29, 2024 | Alnylam ...
WEBSep 29, 2024 · Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile.
Press Releases - Alnylam Pharmaceuticals, Inc.
WEBMay 7, 2024 · Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
Alnylam Pharma’s Promising Clinical Data Tempered by Market …
WEBSep 30, 2024 · The positive echocardiogram and biomarker data from the HELIOS-B study indicate that Alnylam’s drug vutrisiran shows significant benefits for patients with cardiac amyloidosis, particularly in...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is Expected To …
WEB4 days ago · Consensus from 30 of the American Biotechs analysts is that Alnylam Pharmaceuticals is on the verge of breakeven. They anticipate the company to incur a final loss in 2025, before generating ...
Alnylam® Newsroom
WEBRNAi RNAi Therapeutics, from Possibility to Patients. Careers & Culture Alnylam Named a Best Workplace for Innovators for the 4th Year in a Row by Fast Company. Responsibility Alnylam Named a Humankind 100 Company for the 3rd Year in a Row. Press Releases Noteworthy announcements from Alnylam.
Articles | Alnylam® Newsroom
WEBAug 15, 2024 · Articles. May 7, 2024 Alnylam Publishes 2023 Corporate Responsibility Report Alnylam's 2023 Corporate Responsibility Report details our corporate responsibility and ESG efforts and progress. Read More ›. April 26, 2024 Better Together: Alnylam and Organized Customer Health Systems Want to Improve Access and ...
Alnylam Pharmaceuticals, Inc. (ALNY) Latest Stock News
WEBGet the latest Alnylam Pharmaceuticals, Inc. (ALNY) stock news and headlines to help you in your trading and investing decisions.
Alnylam Announces Preliminary* Fourth Quarter and Full Year …
WEBCAMBRIDGE, Mass., January 07, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2023 global...
Better Together: Collaborating for Rare Disease Care, Pharmacy ...
WEB4 days ago · By supporting a network that empowers pharmacists, amplifying patient voices, and fostering strategic collaboration, Alnylam is helping to reshape how patients with rare diseases might navigate their treatment journey.
Alnylam Reports Additional Positive Interim Phase 1 Results for …
WEBOct 25, 2023 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced additional positive interim results for the ongoing single ascending dose portion of the Phase...
- Some results have been removed